🇺🇸 FDA
Pipeline program

Sodium chloride 0.372% solution, Dexamethasone sodium phosphate for encapsulation into autoerythrocytes

IEDAT-04-2022

Phase 3 small_molecule active

Quick answer

Sodium chloride 0.372% solution, Dexamethasone sodium phosphate for encapsulation into autoerythrocytes for Ataxia Telangiectasia is a Phase 3 program (small_molecule) at Quince Therapeutics with 1 ClinicalTrials.gov record(s).

Program details

Company
Quince Therapeutics
Indication
Ataxia Telangiectasia
Phase
Phase 3
Modality
small_molecule
Status
active

Clinical trials